Cargando…

Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center

BACKGROUND: Triptorelin depot is largely used to treat central precocious puberty (CPP) in children, and a 3-month depot has been introduced. However, data about the 3-month gonadotropin-releasing hormone use for treatment of CPP in Korean girls are not available. This study was conducted to compare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Lindsey Yoojin, Kang, Eungu, Nam, Hyo-Kyoung, Rhie, Young-Jun, Lee, Kee-Hyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405405/ https://www.ncbi.nlm.nih.gov/pubmed/34463062 http://dx.doi.org/10.3346/jkms.2021.36.e219

Ejemplares similares

Serum osteocalcin levels in girls with central precocious puberty
por: Rhie, Young Jun, et al.
Publicado: (2013)

Prevalence of idiopathic scoliosis in girls with central precocious puberty: effect of a gonadotropin-releasing hormone agonist
por: Chung, Lindsey Yoojin, et al.
Publicado: (2020)

Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty
por: Jeon, Min Jin, et al.
Publicado: (2021)

Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery
por: Neely, E. Kirk, et al.
Publicado: (2010)

Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort Study
por: Yang, Jianmei, et al.
Publicado: (2022)

Genetic Variations of the KISS1R Gene in Korean Girls with Central Precocious Puberty
por: Oh, Yeon Joung, et al.
Publicado: (2017)

Thyroid function in girls with central precocious puberty
por: Jung, Geehae, et al.
Publicado: (2019)

Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty
por: Kim, You Jin, et al.
Publicado: (2013)

Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Clinical outcome of one-third–dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation
por: Li, Yu, et al.
Publicado: (2012)

KISS1 Gene Polymorphisms in Korean Girls with Central Precocious Puberty
por: Rhie, Young-Jun, et al.
Publicado: (2014)

Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study
por: Klein, Karen O, et al.
Publicado: (2023)

Serum Kisspeptin Levels in Korean Girls with Central Precocious Puberty
por: Rhie, Young Jun, et al.
Publicado: (2011)

Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment
por: Nam, Hyo-Kyoung, et al.
Publicado: (2017)

Pelvic Ultrasound Parameters of Long-Acting Depot Formulation of Leuprorelin in the Treatment of Idiopathic Central Precocious Puberty in Girls
por: Yang, Kun, et al.
Publicado: (2021)

Factors to Predict Positive Results of Gonadotropin Releasing Hormone Stimulation Test in Girls with Suspected Precocious Puberty
por: Nam, Hyo-Kyoung, et al.
Publicado: (2012)

Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
por: Vurallı, Doğuş, et al.
Publicado: (2020)

Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study
por: Lee, Peter A, et al.
Publicado: (2011)

Central Precocious Puberty: Treatment with Triptorelin 11.25 mg
por: Chiocca, Elena, et al.
Publicado: (2012)

Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty
por: Yoo, Eunjoo, et al.
Publicado: (2023)

Use of the Subcutaneous Triptorelin Stimulation Test for Diagnosis of Central Precocious Puberty
por: Ahn, Jungmin, et al.
Publicado: (2023)

Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
por: Baek, Joon-Woo, et al.
Publicado: (2014)

SUN-063 Usefulness of a LHRH Test with Low Dose of Triptorelin Pamoate in the Diagnosis of Precocious Puberty in Girls
por: Llano, Juan Pablo, et al.
Publicado: (2020)

The effect of triptorelin and leuprolide on the level of sex hormones in girls with central precocious puberty and its clinical efficacy analysis
por: Wang, Lan, et al.
Publicado: (2021)

Qualitative assessment of precocious puberty-related user-created contents on YouTube
por: Nam, Hyo-Kyoung, et al.
Publicado: (2015)

Brain magnetic resonance imaging (MRI) findings in central precocious puberty patients: is routine MRI necessary for newly diagnosed patients?
por: Oh, Ye Rim, et al.
Publicado: (2023)

An 11-month-old girl with central precocious puberty caused by hypothalamic hamartoma
por: Yoon, Da Young, et al.
Publicado: (2016)

Precocious puberty in girls
por: Chittwar, Sachin, et al.
Publicado: (2012)

Sustained In-Vivo Release of Triptorelin Acetate from a Biodegradable Silica Depot: Comparison to Pamorelin(®) LA
por: Forsback, Ari-Pekka, et al.
Publicado: (2021)

Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study
por: Luo, Xiaoping, et al.
Publicado: (2023)

Effect of triptorelin 3.75 mg subcutaneously injection every 6 weeks on adult height in girls with idiopathic central precocious puberty
por: Liang, Yan, et al.
Publicado: (2015)

Triptorelin stimulated luteinizing hormone concentrations for diagnosing central precocious puberty: study of diagnostic accuracy
por: Vukovic, Rade, et al.
Publicado: (2021)

Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study
por: Valenzise, M., et al.
Publicado: (2023)

2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents
por: Kim, Su Jin, et al.
Publicado: (2023)

Central precocious puberty due to hypothalamic hamartoma in a six-month-old infant girl
por: Kotwal, Narendra, et al.
Publicado: (2012)

Diagnosis and constitutional and laboratory features of Korean girls referred for precocious puberty
por: Kim, Doosoo, et al.
Publicado: (2012)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
por: Sethi, Rajni, et al.
Publicado: (2009)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
por: Carpiniello, Bernardo, et al.
Publicado: (2016)

Dental Depot
Publicado: (1862)

Cannot write session to /tmp/vufind_sessions/sess_jt3i8ksh261j9g56lfd967fnsk